Zara Baloch, Review Editor | Editorial Board Member at OncoDaily, Director Quantitative Research and Meta Analysis, Digital Education Manager and Host at MedNews Week, shared Adeena Musheer’s, Program Manager at MedNews Week, post on LinkedIn, adding:
“An excellent start to the MedNews Week Clinical Exchange series!
As treatment options in mantle cell lymphoma continue to expand, so do the questions surrounding how best to use them. From moving beyond traditional chemotherapy to understanding where newer therapies fit into the treatment journey, these are decisions that continue to shape clinical practice.
In our inaugural episode, Dr. Kami Maddocks and Dr. Peter Martin offer their expert perspectives on some of the most important developments in MCL, including the evolving role of BTK inhibitors, the promise of CAR-T and bispecific antibodies, and how emerging evidence may influence treatment decisions.
Dr. Peter Martin and Dr. Kami Maddocks
What makes this conversation particularly valuable is the opportunity to hear how two leading lymphoma experts approach the questions that don’t always have straightforward answers.
If you’re interested in where lymphoma treatment is heading, this is a conversation worth watching!
Quoting Adeena Musheer’s post:
“Some conversations stay with you because they go beyond reviewing evidence.
They show you how experts actually think through the grey areas of clinical practice.
I am incredibly excited to share the inaugural episode of MedNews Week Clinical Exchange: Mantle Cell Lymphoma: Where Practice Is Heading, featuring Dr Kami Maddocks and Dr Peter Martin.
This was designed not as a conventional lecture, but as an expert-to-expert clinical exchange built around the crossroads physicians increasingly face in mantle cell lymphoma: when chemotherapy can be avoided, how high-risk biology should change treatment, where MRD belongs in practice, whether BTK inhibitor therapy may eventually become finite.
For me, this episode was particularly meaningful.
During my time at Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, I had the privilege of learning from Dr Maddocks and seeing firsthand the depth of expertise and thoughtfulness she brings to lymphoma care and research.
To later have the opportunity to welcome and host her at MedNews Week was genuinely special.
It was equally an honour to learn from Dr Peter Martin, whose perspective throughout this discussion brought remarkable clarity to some of the most difficult sequencing and treatment questions in MCL.
We also warmly congratulate Dr Martin on receiving the 2026 Distinguished Leadership Award from the Lymphoma Research Foundation, a well-deserved recognition of his contributions to lymphoma research, clinical care, and the field at large.
One of my favourite parts of this conversation was that there was no attempt to reduce complex decisions to a single “correct” algorithm. Instead, we explored where practice may differ, where uncertainty still begins, and how evidence is translated to the individual patient sitting in front of us.
We discussed:
- Chemotherapy-free frontline strategies
- Defining biologically high-risk MCL
- The evolving role of MRD
- Duration of BTK inhibitor therapy
- Relapse after frontline BTK inhibition
- Sequencing pirtobrutinib, CAR-T, and bispecific antibodies
- When the CAR-T conversation should begin
- and what we hope MCL care will look like a decade from now
Thank you to my wonderful co-host Dr. Tuba Basitfor helping guide this exchange with such thoughtfulness.
And finally, immense gratitude to Dr Yan Leyfman and Dr Chandler Park, for their exceptional mentorship and for continuing to create opportunities at MedNewsWeek where trainees can sit at the table with global experts and learn directly from leaders shaping the future of oncology.”
You can also read: Mantle Cell Lymphoma: MANGROVE and the Future of Chemotherapy-Free, Risk-Adapted Treatment.
